dm+d

116076009

Medicine Compliance Aid Stability

genericNon-proprietary

Non-proprietary
generic
Tablets 250mg, 500mg, 750mg, 1 gram
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special requirements for storage.

KeppraUCB Pharma Ltd

UCB Pharma Ltd
Keppra
Tablets f/c 250mg, 500mg, 750mg, 1 gram
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special requirements for storage.
15 January 2013

genericNon-proprietary

Non-proprietary
generic
Tablets 250mg, 500mg, 750mg, 1 gram
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special requirements for storage.
23 February 2015

KeppraUCB Pharma Ltd

UCB Pharma Ltd
Keppra
Tablets f/c 250mg, 500mg, 750mg, 1 gram
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special requirements for storage.
23 February 2015

Lactation Safety Information

Moderate amount of published evidence which shows variable amounts in breast milk, ranging from small to moderate levels.
Levels in infant serum are very low or undetectable
Some infants have experienced drowsiness; additional case reports of hypotonia, vomiting and poor feeding in infants exposed to levetiracetam and other antiepileptics
Monitor infant for sedation, poor feeding, adequate weight gain, and developmental milestones, especially in younger infants and when used in combination with other anti-epileptic drugs
Measurement of an infant’s serum level might help rule out toxicity if there is a concern
If taken during pregnancy, consider maternal dose adjustment to compensate for return to normal renal clearance rates
4 March 2022

New Medicines

Amnestic mild cognitive impairment due to Alzheimer's disease (prodromal Alzheimer's disease)

Information

New formulation (repurposed medicine )
AgeneBio
AgeneBio

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials

Category

Acetylcholine agonist given as a once-daily, extended-release formulation, given at approximately one-twelfth of the dose most commonly prescribed for epilepsy (220mg daily).
Alzheimers disease is the most common form of dementia, accounting for 50%-60% of all cases. The prevalence of dementia is below 1% in individuals aged 60-64 years, but shows an almost exponential increase with age, so that in people aged 85 years or older the prevalence is between 24% and 33% in the Western world
Amnestic mild cognitive impairment due to Alzheimer's disease (prodromal Alzheimer's disease)
Oral